InVivoMAb anti-mouse 4-1BBL (CD137L)

Thomas S, Kuncheria L, Roulstone V, et al. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. J Immunother Cancer. 2019,7(1):214. doi: 10.1186/s40425-019-0682-1

Welten SP, Redeker A, Franken KL, et al. The viral context instructs the redundancy of costimulatory pathways in driving CD8(+) T cell expansion. Elife. 2015,4. doi: 10.7554/eLife.07486

Kurche JS, Burchill MA, Sanchez PJ, et al. Comparison of OX40 ligand and CD70 in the promotion of CD4+ T cell responses. J Immunol. 2010,185(4):2106-15. doi: 10.4049/jimmunol.1000172